Company: MIRM
Filing Date: 2025-04-14
Form Type: DEF 14A
Source: 0001759425-25-000022
Chunk: 0

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-04-14
Form: DEF 14A
Chunk 0
---
### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

#### SCHEDULE 14A INFORMATION

#### Proxy Statement Pursuant to Section 14(a) of the

#### Securities Exchange Act of 1934
<div align='center'>(Amendment No. )

________________</div>

| Filed by the Registrantx |     | Filed by a party other than the Registranto |

Check the appropriate box:

| o |     | Preliminary Proxy Statement                                                     |
| o |     | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| x |     | Definitive Proxy Statement                                                      |
| o |     | Definitive Additional Materials                                                 |
| o |     | Soliciting Material Pursuant to § 240.14a-12                                    |

| Mirum Pharmaceuticals, Inc.                                             |
| (Name of Registrant as Specified In Its Charter)                        |
| N/A                                                                     |
| (Name of Person(s) Filing Proxy Statement if other than the Registrant) |

Payment of Filing Fee (Check all boxes that apply)

| x |     | No fee required                                                                                     |
| o |     | Fee paid previously with preliminary materials                                                      |
| o |     | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |

### TABLE OF CONTENTS
| Notice of Annual Meeting of Stockholders |

Dear Stockholder: You are cordially invited to attend the 2025 Annual Meeting of Stockholders (the “Annual Meeting”) of Mirum Pharmaceuticals, Inc., a Delaware corporation (the “Company”). The Annual Meeting will be held on Thursday, May 29, 2025, at 9:00 a.m. (Pacific Time) in person at the Company’s headquarters. The Annual Meeting is being held for the following purposes: Items of Business

| 1 
 2 |     | To elect the Board’s three Class III nominees for director named in the Proxy Statement to hold office until the Company’s 2028 annual meeting of stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal. 
 To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025.                                                           |